CVRX
CVRx, Inc.
CVRX offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
NVO
Novo Nordisk A/S
NVO has the edge over CVRX overall on the model score.
CVRX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Unavailable |
CVRX's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CVRX PE Valuation
CVRX has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
CVRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Stable | |
| Stable | |
| Limited | |
| Moderate |
Analysts expect CVRX's earnings, revenue and profitability to hold roughly steady.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
CVRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.00 | -$0.02 |
| Q2 2026 | -$1.97 | +$0.09 |
| Q1 2026 | -$2.01 | +$0.13 |
| Q4 2025 | -$2.04 | +$0.61 |
| Q3 2025 | -$1.98 | +$0.73 |
| Q2 2025 | -$2.06 | +$0.51 |
| Q1 2025 | -$2.14 | +$0.34 |
| Q4 2024 | -$2.65 | -$0.66 |
CVRX is still losing money, but less than at its worst: $2.00 per share over the past year, against $2.71 at its worst in late 2024.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over CVRX on earnings quality, reporting a profit while its opponent remains loss making.
CVRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $13.8M | -5.8% |
| Q2 2026 | $15.7M | +16% |
| Q1 2026 | $14.8M | +20% |
| Q4 2025 | $16M | +4.4% |
| Q3 2025 | $14.7M | +9.8% |
| Q2 2025 | $13.6M | +15% |
| Q1 2025 | $12.3M | +15% |
| Q4 2024 | $15.3M | +36% |
CVRX's revenue is growing: $14M last quarter, down 5.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -94% | -11 points |
| Q2 2026 | -83% | +23 points |
| Q1 2026 | -82% | +27 points |
| Q4 2025 | -70% | -2.8 points |
| Q3 2025 | -84% | +14 points |
| Q2 2025 | -106% | +13 points |
| Q1 2025 | -109% | +98 points |
| Q4 2024 | -67% | +19 points |
CVRX's operating margin was −94% last quarter, down 11 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over CVRX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over CVRX on profitability, with a higher operating margin.
CVRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$11M | -$991K |
| Q2 2026 | -$8.9M | -$899K |
| Q1 2026 | -$12.3M | +$595K |
| Q4 2025 | -$9.8M | -$1.8M |
| Q3 2025 | -$10M | +$443K |
| Q2 2025 | -$8M | +$2.1M |
| Q1 2025 | -$12.9M | -$1.1M |
| Q4 2024 | -$8.1M | -$52K |
CVRX has burned cash in almost every quarter: −$42M over the past year, against −$39M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over CVRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
CVRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.8% | +731K shares |
| 1 year | +4.1% | +1.1M shares |
| 3 years | +31% | +6.4M shares |
| 5 years | +7343% | +26.9M shares |
CVRX has 27M diluted shares, up 4.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over CVRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
CVRX Net Leverage
CVRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
CVRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.1 | Oversold |
| Stochastic | 1.7 | Oversold |
CVRX's weekly RSI is 26 (oversold) and its Stochastic is 2 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
CVRX PE vs Healthcare Sector
CVRX has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CVRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.43 | 56% below |
| 20 week MA | $2.88 | 78% below |
| 50 week MA | $5.38 | 88% below |
| 100 week MA | $7.50 | 92% below |
| 200 week MA | $11.1 | 94% below |
CVRX is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over CVRX on trend strength, trading above more of its moving averages.
CVRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $25.5 | $12.2 | -52% |
| 2022 | $12.2 | $16.7 | +37% |
| 2023 | $16.7 | $31.4 | +88% |
| 2024 | $31.4 | $13.2 | -58% |
| 2025 | $13.2 | $7.42 | -44% |
| 2026 YTD | $7.42 | $0.63 | -92% |
CVRX has finished lower in three of the last five years. It's down 92% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over CVRX on returns for 2026, with the stronger performance.